AusperBio

Summary active Updated Aug 31, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Francisco, California
Founded 2020
Latest Stage Series C
Total Raised $360M
Website https://ausperbio.com
Sector
biotech therapeutics hepatitis oligonucleotides

Founders

Guofeng Cheng Co-Founder & CEO

About

AusperBio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antisense oligonucleotide (ASO) therapies for chronic hepatitis B (CHB) and other liver diseases, headquartered in San Francisco with R&D operations in China 12. Its lead candidate, AHB-137, is an unconjugated ASO designed to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication, and promote immune reactivation, with the stated goal of achieving a functional cure for CHB 1. On August 27, 2026, the company closed a $120 million Series C financing, bringing its total capital raised since 2024 to approximately $360 million 123.

Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.

Funding History

Date Round Amount Lead Co-investors
2026-08-27 Series C $120M Undisclosed strategic investor RA Capital Management, HanKang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, CDH Investments 123

What Investors Say

No independently sourced investor quotes available at this time.

What Founders Say

Dr. Guofeng Cheng, co-founder and CEO, on the round: “This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialization.” 1

Sources

  1. BioSpace / PRNewswire, “AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies,” August 27, 2026, accessed August 2026. https://www.biospace.com/press-releases/ausperbio-completes-120-million-series-c-financing-to-advance-ahb-137-toward-potential-commercialization-and-expand-next-generation-hbv-therapies↩↩↩↩↩

  2. DealStreetAsia, “Biopharma firm AusperBio secures $120m Series C to advance chronic hepatitis B therapies,” August 2026, accessed August 2026. https://www.dealstreetasia.com/stories/ausperbio-series-c-round-493578↩↩↩

  3. Yahoo Finance / Pharmaceutical Business Review, “AusperBio raises $120m to progress hepatitis B therapies,” August 2026, accessed August 2026. https://finance.yahoo.com/healthcare/articles/ausperbio-raises-120m-progress-hepatitis-103646269.html↩↩